Jasper Therapeutics (NASDAQ:JSPR) Stock Rated “Outperform” in New Coverage at William Blair

Stock analysts at William Blair began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued to clients and investors on Wednesday. The brokerage set an “outperform” rating on the stock.

JSPR has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Piper Sandler began coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 target price on the stock. Wall Street Zen cut Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.33.

Jasper Therapeutics Trading Up 1.9%

JSPR stock traded up $0.01 on Wednesday, hitting $0.51. 21,408 shares of the company’s stock traded hands, compared to its average volume of 819,857. The stock has a market cap of $16.81 million, a price-to-earnings ratio of -0.32 and a beta of 3.16. Jasper Therapeutics has a 1-year low of $0.32 and a 1-year high of $2.69. The stock has a fifty day moving average of $0.67 and a 200-day moving average of $0.70.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. On average, equities research analysts anticipate that Jasper Therapeutics will post -1.14 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.